2nd Annual Next Generation Sequencing USA Congress 2016

The 2nd Annual Next Generation Sequencing USA Congress, 3-4 October 2016 in Boston, USA features a panel of leading global experts from across genomic and bioinformatics research areas who will address the very latest advances in a range of topics, including clinical and diagnostic applications, epigenetics and transcriptomics, and novel techniques and technologies. Delegates will also have the opportunity to attend our co-located inaugural Genome Editing USA Congress and 2nd Annual Single Cell Analysis Congress, where we will be bringing together some of the top minds working with CRISPR, ZFN and TALENs as well as single cell bioinformatics, microfluidics and more to address the most exciting innovations in genomics.

The Congress will cover 6 interactive streams:

2nd Annual Next Generation Sequencing USA Congress

• Advances in NGS Platforms and Key Therapeutic Applications
• NGS Data Management and Bioinformatics
• NGS Clinical Applications & Diagnostics

 2nd Annual Single Cell Analysis USA Congress

• Single Cell Analysis and Transcriptomics
• Single Cell Analysis Technologies
• Overcoming Key Single Cell Analysis Challenges

The NGS and single cell field is still advancing at a rapid rate, with new potential therapeutic applications increasingly being developed and advances in faster, more precise technologies.  Following on more our renowned international NGS and Single Cell series, this year’s Boston event will attract over 250 delegates.

Researchers will have the opportunity to discover the very latest technologies, hear brand new clinical and diagnostic data, and network with renowned senior academics. The congress will feature 60 presentations from the leading academics in the field, with Professors and Directors from the Broad Institute, MIT, Harvard, UCSF, Stanford, Yale and leading medical institutions, as well as senior representatives from pharmaceutical and biotech companies including AstraZeneca, Biogen and Pfizer.

Some of our most exciting key presentations will include an examination of developments in cancer precision medicine from PathGroup, a look at the NGS experiment lifecycle for a medium-sized biopharma company from Biogen, clinical applications of single cell technologies from MIT, and updates on NGS genomic testing in paediatric cancer from a Senior VP at Phoenix Children’s Hospital. Together with our Genome Editing Congress, this will be an unmissable meeting for anyone working in genomic research.

You can also follow us on Twitter @NGSUSCongress and join the Congress conversation #NGSUS16